SGLT-2-Inhibitors in Heart Failure

{"title":"SGLT-2-Inhibitors in Heart Failure","authors":"","doi":"10.36879/jcr.20.000135","DOIUrl":null,"url":null,"abstract":"Heart failure is a frequent and highly debilitating pathology. Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers, β‐\nblockers, mineralocorticoid receptor antagonists, and valsartan/sacubitril have been shown to reduce mortality in chronic heart failure with\nreduced ejection fraction. Recently, glifozines (SGLT‐2 inhibitors) have become another effective therapeutic option for heart failure with\nreduced ejection fraction, in patients with and without diabetes mellitus. The review presents the effects of SGLT‐2 inhibitors on the\ncardiovascular system and heart failure.","PeriodicalId":15200,"journal":{"name":"Journal of Cardiology & Current Research","volume":"85 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiology & Current Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36879/jcr.20.000135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Heart failure is a frequent and highly debilitating pathology. Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers, β‐ blockers, mineralocorticoid receptor antagonists, and valsartan/sacubitril have been shown to reduce mortality in chronic heart failure with reduced ejection fraction. Recently, glifozines (SGLT‐2 inhibitors) have become another effective therapeutic option for heart failure with reduced ejection fraction, in patients with and without diabetes mellitus. The review presents the effects of SGLT‐2 inhibitors on the cardiovascular system and heart failure.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
sglt -2抑制剂在心力衰竭中的应用
心力衰竭是一种常见且高度衰弱的病理。血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂、β受体阻滞剂、矿皮质激素受体拮抗剂和缬沙坦/沙比利已被证明可以降低慢性心力衰竭患者的死亡率,同时降低射血分数。最近,格列嗪(SGLT‐2抑制剂)已成为伴有射血分数降低的心力衰竭的另一种有效治疗选择,适用于伴有或不伴有糖尿病的患者。本文综述了SGLT‐2抑制剂对心血管系统和心力衰竭的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Prevalence of delirium in the postoperative period of cardiac surgery AL amyloidosis masquerading as cardiac syncope: a case report Etiological profile of acute pericarditis at the Yalgado-Ouedraogo university hospital in Ouagadougou at Burkina Faso Pilot experience with VV ECLS in a single hospital in a developing nation COVID 19 infection requiring ECMO support after Fontan operation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1